Gary Lyons Biography and Net Worth

Director of Neurocrine Biosciences

Gary A. Lyons has served on the Board of Directors since joining Neurocrine Biosciences in February 1993. Mr. Lyons served as the President and Chief Executive Officer of the Company from February 1993 through January 2008. Prior to joining the Company, Mr. Lyons held a number of senior management positions at Genentech, Inc., including Vice President of Business Development and Vice President of Sales. Mr. Lyons is currently the Chairman of the Board of Directors for each of Rigel Pharmaceuticals, Inc., a biotechnology company focused on developing drugs for the treatment of inflammatory/autoimmune and metabolic diseases, and Travere Therapeutics, an ultra-orphan disease commercial-stage company. Mr. Lyons is a member of the Board of Directors of Brickell Biotech, Inc., a biotechnology company focused on debilitating skin diseases, and Eledon Pharmaceuticals, Inc. (formerly Novus Therapeutics), a biotechnology company focused on immunology therapeutics. Mr. Lyons was previously a director of Neurogesx, Cytori Therapeutics, and Facet Biotech Corporation. Mr. Lyons holds a B.S. in Marine Biology from the University of New Hampshire and an M.B.A. from Northwestern University’s J.L. Kellogg Graduate School of Management.

What is Gary A. Lyons' net worth?: The estimated net worth of Gary A. Lyons is at least $5.83 million as of October 4th, 2024. Mr. Lyons owns 51,000 shares of Neurocrine Biosciences stock worth more than $5,831,085 as of March 26th. This net worth approximation does not reflect any other assets that Mr. Lyons may own. Learn More about Gary A. Lyons' net worth.
How do I contact Gary A. Lyons?: The corporate mailing address for Mr. Lyons and other Neurocrine Biosciences executives is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. Neurocrine Biosciences can also be reached via phone at (858) 617-7600 and via email at ir@neurocrine.com. Learn More on Gary A. Lyons' contact information.
Has Gary A. Lyons been buying or selling shares of Neurocrine Biosciences?: Gary A. Lyons has not been actively trading shares of Neurocrine Biosciences during the past quarter. Most recently, Gary A. Lyons sold 11,570 shares of the business's stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $150.43, for a transaction totalling $1,740,475.10. Following the completion of the sale, the director now directly owns 119,047 shares of the company's stock, valued at $17,908,240.21. Learn More on Gary A. Lyons' trading history.
Who are Neurocrine Biosciences' active insiders?: Neurocrine Biosciences' insider roster includes Matt Abernethy (CFO), Eric Benevich (Insider), David Boyer (Insider), Julie Cooke (Insider), Ingrid Delaet (Insider), Kyle Gano (Insider), Kevin Gorman (CEO), Dimitri Grigoriadis (Insider), Darin Lippoldt (Insider), Malcolm Lloyd-Smith (Insider), Gary Lyons (Director), George Morrow (Director), Leslie Norwalk (Director), Jude Onyia (Insider), Richard Pops (Director), William Rastetter (Director), Eiry Roberts (Insider), Shalini Sharp (Director), and Stephen Sherwin (Director). Learn More on Neurocrine Biosciences' active insiders.
Are insiders buying or selling shares of Neurocrine Biosciences?: During the last year, insiders at the sold shares 31 times. They sold a total of 397,095 shares worth more than $56,999,971.93. The most recent insider tranaction occured on February, 13th when CFO Matt Abernethy sold 2,558 shares worth more than $298,927.88. Insiders at Neurocrine Biosciences own 4.3% of the company. Learn More about insider trades at Neurocrine Biosciences.
Information on this page was last updated on 2/13/2025.

Gary A. Lyons Insider Trading History at Neurocrine Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/13/2024	Sell	11,570	$150.43	$1,740,475.10	119,047
7/16/2024	Sell	930	$150.03	$139,527.90	119,047
5/14/2024	Sell	12,500	$135.63	$1,695,375.00	116,947
12/1/2023	Sell	5,000	$116.77	$583,850.00	203,697
9/12/2023	Sell	5,000	$115.02	$575,100.00	203,697
9/1/2023	Sell	5,000	$110.06	$550,300.00	203,697
10/31/2022	Sell	15,000	$114.76	$1,721,400.00	203,697
10/4/2022	Sell	5,000	$110.54	$552,700.00	203,697
4/25/2022	Sell	15,000	$92.76	$1,391,400.00	208,697
10/7/2021	Sell	5,000	$105.06	$525,300.00
6/10/2021	Sell	10,000	$100.27	$1,002,700.00
1/25/2021	Sell	1,600	$120.03	$192,048.00
11/8/2019	Sell	5,000	$110.00	$550,000.00	225,697
11/1/2019	Sell	5,000	$100.22	$501,100.00	230,697
7/30/2019	Sell	10,000	$92.07	$920,700.00	235,697
11/2/2018	Sell	15,000	$114.41	$1,716,150.00
6/13/2018	Sell	15,000	$99.24	$1,488,600.00	260,697
2/15/2018	Sell	5,000	$84.67	$423,350.00
2/5/2018	Sell	5,000	$83.08	$415,400.00	267,066
12/1/2017	Sell	10,000	$72.92	$729,200.00	272,066
9/18/2015	Sell	15,000	$54.89	$823,350.00	252,066
3/24/2015	Sell	30,000	$41.53	$1,245,900.00
9/15/2014	Sell	20,000	$15.66	$313,200.00

See Full Table

Gary A. Lyons Buying and Selling Activity at Neurocrine Biosciences

Neurocrine Biosciences Company Overview

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Today's Range

Now: $114.34

$113.05

$116.23

50 Day Range

MA: $125.89

$107.22

$153.29

2 Week Range

Now: $114.34

$105.18

$157.98

Volume

495,314 shs

Average Volume

1,312,634 shs

Market Capitalization

$11.40 billion

P/E Ratio

34.75

Dividend Yield

N/A

Beta

0.35